Rheumatoid Arthritis (RA) is the most common autoimmune inflammatory arthritis in adults and often negatively impacts patients’ quality of life and ability to perform daily activities.
To help decision-makers identify high-value treatments for patients with RA, the IVI-RA model simulates the lifetime costs and benefits of different strategies for treating patients with moderate to severe rheumatoid arthritis.
The most recent version of the IVI-RA model (released January 2020) includes updates to included therapies and updates to underlying evidence. Important changes include the following:
- Additional treatment options (triple therapy, Janus Kinase uptake inhibitors, sarilumab, and biosimilars)
- Updated treatment effect estimates based on additional randomized controlled evidence
- Updated cost estimates